Lilly Pulitzer’s Sunshine Sale is here, and it’s brimming with vibrant dresses, blouses, and more fashion finds up to 78 percent off. Whether you’re hoping to refresh your wardrobe with ...

The 2025 Lilly Pulitzer Sunshine Sale has up to 70% off activewear, dresses, sweaters, accessories, home decor, and more. This rare event happens twice a year—shop now before your favorites sell ...

Learn more. Guess what? Lilly Pulitzer just added a bunch of new styles to the 2024 Sunshine Sale, and they’re up to 70% ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...

On Oct. 30, Lilly told investors to expect 2024 revenue to land in a range between $45.4 billion and $46 billion. Sales of the company's diabetes and weight loss treatments are soaring but not ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...

The Pulitzer Prize board is asking a judge to hit pause on a defamation case President Donald Trump filed against it until his presidency is over, using Trump’s own legal arguments against him.

Gift 5 articles to anyone you choose each month when you subscribe. Sales at Chemist Warehouse rose to more than $5 billion over the last six months ahead of the discount pharmacy giant’s ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...